Limbus acquires Nostos: Accelerating the path to Europe’s leading genetic diagnostics software solution
Rostock, Germany, September 15, 2025 — Limbus, the company behind the innovative varvis® software for genomic data analysis, today announced the acquisition of Nostos Genomics, a fellow pioneer in AI-driven medical software solutions. This acquisition unites two leaders in genomic software – combining Limbus’ clinical-grade workflows with Nostos’ cutting-edge AI technology for variant interpretation.
“We are excited about the opportunities this acquisition brings – not only for our product portfolio, but also for our team,” said Ben Liesfeld, CEO of Limbus. “We have a deep respect for what Nostos has achieved, and we’re honored to carry that legacy forward together with their incredible team. Their expertise will help us scale our impact and accelerate the development of cutting-edge solutions in personalized medicine.”
Limbus is thrilled to welcome the talented team behind Nostos into its growing family, including co-founders David Gorgan and Rocío Acuña Hidalgo, who will continue to play key roles in the integration and future development of the combined platform. “Joining Limbus lets us bring our product AION to more laboratories across Europe while continuing to deliver the speed and confidence our customers rely on,” said David Gorgan. “By pairing AION’s AI-driven interpretation with the varvis® software’s robust clinical workflows, we can deliver more comprehensive and scalable analysis where it matters most, benefiting clinical professionals and patients alike,” added Rocío Acuña Hidalgo.
Limbus and Nostos will continue to operate independently with continued support for existing customers. In parallel, the companies will pursue a phased, deep integration of AION into the varvis® software to deliver a unified, IVDR-compliant, end-to-end solution for genetic diagnostics. Building on the varvis® software’s market leadership in Germany, the combined strengths position Limbus as Europe’s foremost provider of regulatory-grade genetic diagnostics software.
Both companies share a vision for a future where digital solutions empower clinicians, researchers, and patients alike. With the varvis® software at the core of Limbus’ offering, and the innovative strengths of Nostos now part of the team, the path ahead promises even greater value for customers. Limbus is confident that integrating the teams and technologies will drive meaningful innovation and durable growth – together.
About Limbus
Limbus Medical Technologies GmbH is a Germany-based, privately held company specializing in medical software for genomics. Its flagship product, the varvis® software, supports clinical diagnostics and research by enabling fast, accurate, and scalable analysis of genetic data.
About Nostos
Nostos Genomics GmbH is a privately held company founded in 2018 in Berlin, Germany, on a mission to apply AI to genomic interpretation for patients with rare diseases. AION, an AI-powered decision-support solution that streamlines the prioritization of genetic variants, helps healthcare professionals make faster, more confident diagnostic decisions.
Limbus acquires Nostos: Accelerating the path to Europe’s leading genetic diagnostics software solution
Rostock, Germany, September 15, 2025 — Limbus, the company behind the innovative varvis® software for genomic data analysis, today announced the acquisition of Nostos Genomics, a fellow pioneer in AI-driven medical software solutions. This acquisition unites two leaders in genomic software – combining Limbus’ clinical-grade workflows with Nostos’ cutting-edge AI technology for variant interpretation.
“We are excited about the opportunities this acquisition brings – not only for our product portfolio, but also for our team,” said Ben Liesfeld, CEO of Limbus. “We have a deep respect for what Nostos has achieved, and we’re honored to carry that legacy forward together with their incredible team. Their expertise will help us scale our impact and accelerate the development of cutting-edge solutions in personalized medicine.”
Limbus is thrilled to welcome the talented team behind Nostos into its growing family, including co-founders David Gorgan and Rocío Acuña Hidalgo, who will continue to play key roles in the integration and future development of the combined platform. “Joining Limbus lets us bring our product AION to more laboratories across Europe while continuing to deliver the speed and confidence our customers rely on,” said David Gorgan. “By pairing AION’s AI-driven interpretation with the varvis® software’s robust clinical workflows, we can deliver more comprehensive and scalable analysis where it matters most, benefiting clinical professionals and patients alike,” added Rocío Acuña Hidalgo.
Limbus and Nostos will continue to operate independently with continued support for existing customers. In parallel, the companies will pursue a phased, deep integration of AION into the varvis® software to deliver a unified, IVDR-compliant, end-to-end solution for genetic diagnostics. Building on the varvis® software’s market leadership in Germany, the combined strengths position Limbus as Europe’s foremost provider of regulatory-grade genetic diagnostics software.
Both companies share a vision for a future where digital solutions empower clinicians, researchers, and patients alike. With the varvis® software at the core of Limbus’ offering, and the innovative strengths of Nostos now part of the team, the path ahead promises even greater value for customers. Limbus is confident that integrating the teams and technologies will drive meaningful innovation and durable growth – together.
About Limbus
Limbus Medical Technologies GmbH is a Germany-based, privately held company specializing in medical software for genomics. Its flagship product, the varvis® software, supports clinical diagnostics and research by enabling fast, accurate, and scalable analysis of genetic data.
About Nostos
Nostos Genomics GmbH is a privately held company founded in 2018 in Berlin, Germany, on a mission to apply AI to genomic interpretation for patients with rare diseases. AION, an AI-powered decision-support solution that streamlines the prioritization of genetic variants, helps healthcare professionals make faster, more confident diagnostic decisions.